Abstract: A method of forming hemostatic sheets. Dextran and water are mixed to form a dextran-water mixture. The dextran-water mixture is formed into a first support layer. Fibrinogen and thrombin are mixed to form a fibrinogen and thrombin mixture. The fibrinogen and thrombin mixture is dispersed on the first support layer to form a hemostatic sheet.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: A hemostatic product that includes a dextran support, at least one hemostatic agent and at least one hemostatic agent stabilizer. The at least one hemostatic agent is selected from the group consisting of thrombin and fibrinogen. The at least one hemostatic agent is associated with the dextran support. The at least one hemostatic agent stabilizer is associated with the at least one hemostatic agent.

Abstract: A method of inducing hemostasis in a wound using a hemostatic product. A dextran support is provided. At least one hemostatic agent stabilizer is mixed with at least one hemostatic agent to form a hemostatic agent and stabilizer mixture. The at least one hemostatic agent includes at least one of thrombin and fibrinogen. The hemostatic agent and stabilizer mixture is associated with the dextran support. The hemostatic product is applied to the wound in which a bodily fluid is present. The at least one hemostatic agent is released from the hemostatic product to induce hemostasis in the wound.

Abstract: Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

Abstract: Therapeutic devices and methods according to embodiments of the invention encourage or cause clitoral engorgement to assist in the treatment of female sexual dysfunction. A vacuum is created over the clitoris, or suction is applied to the clitoris, to create a negative pressure in the clitoris that is lower than the systolic blood pressure. This tends to promote engorgement of the clitoris with blood.

Abstract: Therapeutic devices and methods according to embodiments of the invention alleviate e.g. urinary incontinence in female and male patients. Suction or vacuum, for example, is applied to the genital region, clitoris or clitoral region, the external urethral orifice, and/or other designated areas, e.g. physically stimulating the sacral/pudendal nerves and/or nerve roots and alleviating incontinence. Such embodiments also can encourage or cause clitoral engorgement, or otherwise promote blood flow in the genital region. Vacuum or suction applied to e.g. the clitoris creates a negative pressure in the clitoris that is lower than the systolic blood pressure, tending to promote engorgement of the clitoris with blood. Aspects of the invention are applicable not only to treatment of urinary and fecal incontinence, but also to the treatment of female sexual dysfunction. Aspects of the invention are also applicable to treatment of male incontinence and male erectile dysfunction.

Abstract: Devices and methods according to embodiments of the invention measure physiological changes that occur in the female during sexual arousal. These include changes in clitoral, vaginal-artery, and/or vaginal-capillary blood flow, clitoral engorgement, and bioimpedance, to name a few. Feedback devices and methods assist a patient or medical professional to determine when arousal occurs and what its best triggers are for a particular patient. Overnight arousal-event monitoring, or other continuous monitoring over extended periods of time, either at home or away from home, allows diagnosis of vasculogenic impairment or other problems. The effects of medicinal therapies aimed at female sexual dysfunction can be quantified and used to titrate proper dosages. Embodiments of the invention provide objective, quantifiable measures of multiple physiological variables associated with female arousal, in a manner heretofore unseen in the prior art.